BioMarin Pharmaceuticals
BMRN
543 hedge funds and large institutions have $12B invested in BioMarin Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 91 funds opening new positions, 202 increasing their positions, 184 reducing their positions, and 92 closing their positions.
75% more funds holding in top 10
Funds holding in top 10: 4 → 7 (+3)
1.4% more ownership
Funds ownership: 94.78% → 96.17% (+1.4%)
10% more repeat investments, than reductions
Existing positions increased: 202 | Existing positions reduced: 184
10% more call options, than puts
Call options by funds: $141M | Put options by funds: $128M
1% less first-time investments, than exits
New positions opened: 91 | Existing positions closed: 92
5% less capital invested
Capital invested by funds: $12.7B → $12B (-$631M)
2% less funds holding
Funds holding: 553 → 543 (-10)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$167M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$67.1M |
| 3 |
BlackRock
New York
|
+$59.6M |
| 4 |
Dodge & Cox
San Francisco,
California
|
+$56.8M |
| 5 |
Viking Global Investors
Stamford,
Connecticut
|
+$50.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$84.8M |
| 2 |
1832 Asset Management
Toronto,
Ontario, Canada
|
-$81.8M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$54.7M |
| 4 |
Neuberger Berman Group
New York
|
-$53.8M |
| 5 |
Primecap Management
Pasadena,
California
|
-$45.4M |
BMRN Hedge Fund Activity: Q4 2024 in Review
543 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q4 2024, worth a combined $12B — down 5% from $12.7B a quarter earlier.
Sellers outnumbered buyers: 92 funds closed out of BMRN and 91 opened new positions — a net loss of 1 holder — while 184 trimmed existing stakes and 202 added.
The largest buyer was Capital Research Global Investors, adding an estimated $167M. The largest seller was JP Morgan Chase, cutting an estimated $84.8M.
- 543 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q4 2024, down from 553 in Q3 2024.
- Funds reported $12B of BioMarin Pharmaceuticals stock for Q4 2024, down 5% quarter-over-quarter.
- 91 funds opened new BioMarin Pharmaceuticals positions in Q4 2024 and 92 closed out, a net change of -1 holder.
- The largest BioMarin Pharmaceuticals buyer in Q4 2024 was Capital Research Global Investors, an estimated $167M added.
- The largest BioMarin Pharmaceuticals seller in Q4 2024 was JP Morgan Chase, an estimated $84.8M sold.
Based on aggregated 13F filings for Q4 2024.